DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/k3qh58/orencia_systemic) has announced the addition of the "Orencia (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022" report to their offering.
Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can affect any organ or tissue and is the prototypic autoimmune disease. While SLE can affect multiple major organ systems in the body, one of its most severe manifestations includes renal (kidney) involvement, known as lupus nephritis (LN).
The term LN refers to SLE patients with glomerulonephritis, and when the term LN is used, glomerular tissue injury in the kidneys is always involved. Renal injury without any glomerular involvement is classified as nephritis in a patient with SLE.
Orencia (abatacept) is a marketed drug for the treatment of RA and polyarticular juvenile idiopathic arthritis. It was developed by Bristol-Myers Squibb (BMS) and is being evaluated as a potential treatment for patients with LN.
- Overview of SLE-LN, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Orencia including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Orencia for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan
For more information visit http://www.researchandmarkets.com/research/k3qh58/orencia_systemic
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.